Microarray gene expression profiling in clear cell renal cell carcinoma: prognosis and drug target identification
CA 2442820 A1 · Owner: Van Andel Institute · Inventors: Rhodes, Daniel; Teh, Bin Tean; Haab, Brian
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A nucleic acid probe or a novel set of such probes in a microarray is provided. The probe or probe set is useful in the prognosis of patients with clear cell renal cell carcinoma (CC-RCC) wherein aggressive and non-agressive , CC-RCC tumor types are characterized by differential expression profiles of genes that hybridize with one or more of these probes. Microarrays and kits for carrying out expression profiling of tumor and normal tissue and methods of using them are disclosed.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed March 29, 2002. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended March 29, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by March 29, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.